Is a multinational biotechnology company founded and headquartered in France. The company specializes in the field of in vitro diagnostics for the medical and industrial sectors. The group designs, develops, and produces a wide range of diagnosis systems for medicine and industry.
A world leader in the field of in vitro diagnostics for over 40 years, bioMérieux is present in more than 150 countries through 35 subsidiaries and a large network of distributors. In 2006, revenues reached over €1 billion with 83% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Their products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on Eurolist by Euronext. Other information can be found at www.biomerieux.com.
Alain Mérieux the founder of the company in 1963 is still the main shareholder of bioMerieux. Institut Mérieux no longer exists as a company, its activity is now in Sanofi Aventis.